Posted on 288
Global Coalition for Adaptive Research (LOS ANGELES, CA), Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA, SYDNEY, Australia), and Kintara Therapeutics, Inc. (NASDAQ: KTRA, SAN DIEGO, CA) The Global Coalition for Adaptive Research (GCAR) in collaboration with Kazia and Kintara, today announced the activation of Kazia’s
paxalisib and Kintara’s
VAL-083 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment). GBM AGILE is a revolutionary patient-centered, adaptive platform trial for registration that tests multiple therapies for patients with newly-diagnosed and recurrent glioblastoma (GBM) – the deadliest form of brain cancer.
Kazia’s
paxalisib and Kintara’s
VAL-083 are entering the GBM AGILE trial, which initially opened in July 2019 and has screened over 370 patients to date.
Some of the Top Pharmaceutical Companies to Watch in New Year 2021
“Glioblastoma is the most common and aggressive cancerous brain tumour in adults due to its resistance to therapy. Treatment usually involves surgery, followed by chemotherapy and radiation therapy. Despite these intensive efforts, in most cases tumour cells regrow after treatment and the cancer recurs,” reports Science Daily. However, there may be a treatment option with the development of Berubicin, an anthracycline anticancer drug used for the treatment of malignant gliomas, as noted by Targeted Oncology.
As reported by Grand Review Research, “According to U.S. National Cancer Institute GBM is considered as the most aggressive form of brain cancer which represents 15.4% of all primary brain tumors and about 60% - 75% of all astrocytoma and shows rapid growth rate of benign cells in the organ. Currently unavailable therapies and prognosis for the treatment of GBM is expected to impact the marke
E-Mail
When the COVID-19 pandemic reached Africa, the continent was already struggling to deal with another public health crisis - a growing cancer epidemic characterized by more than one million new cancer cases and nearly 700,000 deaths per year. In a Perspective, Beatrice Wiafe Addai and Wilfred Ngwa discuss the significant challenges COVID-19 imposed on cancer prevention and control in Africa and how the efforts to address these challenges highlight key opportunities where greater investment could improve cancer care globally. At the start of the pandemic, many African governments were forced to rapidly divert already limited medical and healthcare resources away from cancer patients to treat those infected with SARS-CoV-2 and slow the spread of COVID-19. According to the authors, many African countries curtailed or cut cancer prevention activities, including awareness education and outreach, early detection screening, and vaccination, gaps that are likely to persist beyond th
It was found that antibodies themselves may not be giving the protection, they might just be a sign that other parts of the immune system, such as T cells, are able to fight off any new exposures to the virus.
Antibodies after COVID-19 provide some protection, 2 new studies find
Updated Dec 24, 2020;
Posted Dec 24, 2020
One study, published Wednesday by the New England Journal of Medicine, involved more than 12,500 health workers at Oxford University Hospitals in the United Kingdom. Among the 1,265 who had coronavirus antibodies at the outset, only two had positive results on tests to detect active infection in the following six months and neither developed symptoms. (NIAID-RML via AP)AP
Facebook Share
Two new studies give encouraging evidence that having COVID-19 may offer some protection against future infections. Researchers found that people who made antibodies to the coronavirus were much less likely to test positive again for up to six months and maybe longer.